Download PDF
J Pediatr Infect Dis 2024; 19(04): 227-234
DOI: 10.1055/s-0044-1787730
Original Article

Comparison of Characteristics and Outcomes of Multisystem Inflammatory Syndrome and Prepandemic Kawasaki's Disease

Neşe Ünlü
1   Department of Pediatrics, Bağcılar Training and Research Hospital, University of Health Sciences, Istanbul, Türkiye
,
Abdulrahman Özel 
2   Department of Pediatrics, Pediatric Intensive Care Unit, Bağcılar Training and Research Hospital, University of Health Sciences, Istanbul, Türkiye
,
Övgü Büke
1   Department of Pediatrics, Bağcılar Training and Research Hospital, University of Health Sciences, Istanbul, Türkiye
,
Sertaç Hanedan Onan
3   Department of Pediatrics, Clinic of Pediatric Cardiology, Bağcılar Training and Research Hospital, University of Health Sciences, Istanbul, Türkiye
,
Aslıhan Tenekecigil
4   Department of Medical Biochemistry, Bagcılar Research and Education Hospital, University of Health Sciences, Istanbul, Türkiye
5   Department of Medical Biochemistry, Faculty of Medicine, Gazi University, Ankara, Türkiye
,
Meltem Erol
1   Department of Pediatrics, Bağcılar Training and Research Hospital, University of Health Sciences, Istanbul, Türkiye
6   Department of Pediatrics, Division of Adolescent Medicine, Institute of Child Health, Istanbul University, Istanbul, Türkiye
,
Özlem Bostan Gayret
1   Department of Pediatrics, Bağcılar Training and Research Hospital, University of Health Sciences, Istanbul, Türkiye
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Objective In this study, our objective is to compare the demographic, clinical, laboratory, and echocardiographic findings of patients with multisystem inflammatory syndrome in children (MIS-C) and Kawasaki's disease (KD) diagnosed in the prepandemic period.

Methods We retrospectively collected data from all pediatric patients who met the Centers for Disease Control and Prevention's MIS-C case definition and who met the American Heart Association's definition of complete KD before the coronavirus disease 2019 pandemic.

Results A total of 37 patients diagnosed with MIS-C and 40 patients diagnosed with complete KD were included. Gastrointestinal findings were significantly higher in the MIS-C group than in the KD group (vomiting [p = 0.009], diarrhea [p = 0.009]). The incidence of thrombocytopenia (48.6%) was significantly higher in the MIS-C group. Regarding inflammatory markers, procalcitonin and ferritin were significantly higher in the MIS-C group (p = 0.032 and p = 0.006) and the erythrocyte sedimentation rate was higher in the KD group (p < 0.001). Pericardial effusion and mitral valve regurgitation were significantly more frequent in the MIS-C group (p = 0.024 and p = 0.001).

Conclusion Although they have similar findings, our current study findings show that MIS-C and KD differ from each other with different clinical and laboratory features. We think that these differences will help clinicians in diagnosis and patient management.

Keywords

MIS-C - Kawasaki - inflammation - myocardial


Publication History

Received: 24 November 2023

Accepted: 21 May 2024

Article published online:
19 July 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323 (13) 1239-1242
    CrossrefPubMedGoogle Scholar
  • 2 Özel A, Erol M, Onan SH. et al. Evaluation of clinical features of patients diagnosed with MIS-C. Bağcılar Medical Bulletin 2021; 6 (03) 295-301
    CrossrefPubMedGoogle Scholar
  • 3 Verdoni L, Mazza A, Gervasoni A. et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 2020; 395 (10239): 1771-1778
    CrossrefPubMedGoogle Scholar
  • 4 Feldstein LR, Rose EB, Horwitz SM. et al; Overcoming COVID-19 Investigators, CDC COVID-19 Response Team. Multisystem inflammatory syndrome in US. Children and adolescents. N Engl J Med 2020; 383 (04) 334-346
    CrossrefPubMedGoogle Scholar
  • 5 Haslak F, Barut K, Durak C. et al. Clinical features and outcomes of 76 patients with COVID-19-related multi-system inflammatory syndrome in children. Clin Rheumatol 2021; 40 (10) 4167-4178
    CrossrefPubMedGoogle Scholar
  • 6 Royal College of Paediatrics and Child Health. Guidance: Paediatric Multisystem Inflammatory Syndrome Temporally Associated with COVID-19. Accessed 2023, https://www.rcpch.ac.uk/sites/default/files/2020-05/COVID-19-Paediatric-multisystem-%20inflammatory%20syndrome-20200501.pdf
    PubMedGoogle Scholar
  • 7 World Health Organization. Multisystem inflammatory syndrome in children and adolescents with COVID-19: scientific brief. 2020 Accessed 2023. https://iris.who.int/bitstream/handle/10665/332095/WHO-2019-nCoV-Sci_Brief-Multisystem_Syndrome_Children-2020.1-eng.pdf?sequence=1
    PubMedGoogle Scholar
  • 8 Loke YH, Berul CI, Harahsheh AS. Multisystem inflammatory syndrome in children: is there a linkage to Kawasaki disease?. Trends Cardiovasc Med 2020; 30 (07) 389-396
    CrossrefPubMedGoogle Scholar
  • 9 Henderson LA, Canna SW, Friedman KG. et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 2. Arthritis Rheumatol 2021; 73 (04) e13-e29
    CrossrefPubMedGoogle Scholar
  • 10 McCrindle BW, Rowley AH, Newburger JW. et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 2017; 135 (17) e927-e999
    CrossrefPubMedGoogle Scholar
  • 11 Stanley F.. Reference intervals for laboratory tests and procedures. Nelson Textbook of Pediatrics. 20th ed.. Philadelphia: Elsevier; 2016: 2466.e6 :chap 708
    Google Scholar
  • 12 U.S. Department of Health and Human Services Centers for Disease Control and Prevention. CSTE/CDC Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARSCoV- 2 Infection Surveillance Interim Case Reporting Guide. 2022 Accessed 2023, https://www.cdc.gov/mis/pdfs/mis-c_interim-case-reporting-guidance.pdf
    PubMedGoogle Scholar
  • 13 Cem E, Böncüoğlu E, Kıymet E. et al. Which findings make multisystem inflammatory syndrome in children different from the pre-pandemic Kawasaki disease?. Pediatr Cardiol 2023; 44 (02) 424-432
    CrossrefPubMedGoogle Scholar
  • 14 Otar Yener G, Paç Kısaarslan A, Ulu K. et al. Differences and similarities of multisystem inflammatory syndrome in children, Kawasaki disease and macrophage activating syndrome due to systemic juvenile idiopathic arthritis: a comparative study. Rheumatol Int 2022; 42 (05) 879-889
    CrossrefPubMedGoogle Scholar
  • 15 Kostik MM, Bregel LV, Avrusin IS. et al. Distinguishing between multisystem inflammatory syndrome, associated with COVID-19 in children and the Kawasaki disease: development of preliminary criteria based on the data of the retrospective multicenter cohort study. Front Pediatr 2021; 9: 787353
    CrossrefPubMedGoogle Scholar
  • 16 Sobh A, Mosa DM, Khaled N. et al. How multisystem inflammatory syndrome in children discriminated from Kawasaki disease: a differentiating score based on an inception cohort study. Clin Rheumatol 2023; 42 (04) 1151-1161
    CrossrefPubMedGoogle Scholar
  • 17 Lam JY, Shimizu C, Tremoulet AH. et al; Pediatric Emergency Medicine Kawasaki Disease Research Group, CHARMS Study Group. A machine-learning algorithm for diagnosis of multisystem inflammatory syndrome in children and Kawasaki disease in the USA: a retrospective model development and validation study. Lancet Digit Health 2022; 4 (10) e717-e726
    CrossrefPubMedGoogle Scholar
  • 18 Cherqaoui B, Koné-Paut I, Yager H, Bourgeois FL, Piram M. Delineating phenotypes of Kawasaki disease and SARS-CoV-2-related inflammatory multisystem syndrome: a French study and literature review. Rheumatology (Oxford) 2021; 60 (10) 4530-4537
    CrossrefPubMedGoogle Scholar
  • 19 Yilmaz Ciftdogan D, Ekemen Keles Y, Cetin BS. et al. COVID-19 associated multisystemic inflammatory syndrome in 614 children with and without overlap with Kawasaki disease-Turk MIS-C study group. Eur J Pediatr 2022; 181 (05) 2031-2043
    CrossrefPubMedGoogle Scholar
  • 20 Ebina-Shibuya R, Namkoong H, Shibuya Y, Horita N. Multisystem inflammatory syndrome in children (MIS-C) with COVID-19: insights from simultaneous familial Kawasaki disease cases. Int J Infect Dis 2020; 97: 371-373
    CrossrefPubMedGoogle Scholar
  • 21 Rhim JW, Kang JH, Lee KY. Etiological and pathophysiological enigmas of severe coronavirus disease 2019, multisystem inflammatory syndrome in children, and Kawasaki disease. Clin Exp Pediatr 2022; 65 (04) 153-166
    CrossrefPubMedGoogle Scholar
  • 22 Kole MT, Yükselmiş U, Genç FA. et al. Multisystem inflammatory syndrome in children (MIS-C) with COVID-19: a single-center experience. J Pediatr Infect Dis 2022; 17 (04) 200-208
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Kabeerdoss J, Pilania RK, Karkhele R, Kumar TS, Danda D, Singh S. Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations and management. Rheumatol Int 2021; 41 (01) 19-32
    CrossrefPubMedGoogle Scholar
  • 24 Fernández-Cooke E, Grasa CD, Domínguez-Rodríguez S. et al; KAWA-RACE Study Group. Prevalence and clinical characteristics of SARS-CoV-2 confirmed and negative Kawasaki disease patients during the pandemic in Spain. Front Pediatr 2021; 8: 617039
    CrossrefPubMedGoogle Scholar
  • 25 Menikou S, Langford PR, Levin M. Kawasaki disease: the role of immune complexes revisited. Front Immunol 2019; 10: 1156
    CrossrefPubMedGoogle Scholar
  • 26 Sharma C, Ganigara M, Galeotti C. et al. Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison. Nat Rev Rheumatol 2021; 17 (12) 731-748
    CrossrefPubMedGoogle Scholar
  • 27 Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020; 395 (10237): 1607-1608
    CrossrefPubMedGoogle Scholar
  • 28 Yeo WS, Ng QX. Distinguishing between typical Kawasaki disease and multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2. Med Hypotheses 2020; 144: 110263
    CrossrefPubMedGoogle Scholar